REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA
Clinical trials for REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Vitamin d boost may extend life in lymphoma patients, trial hopes
Disease control OngoingThis study looks at whether giving vitamin D supplements to people with newly diagnosed lymphoma or chronic lymphocytic leukemia who have low vitamin D levels can improve their survival and delay the need for treatment. About 565 participants are being given vitamin D3 or a place…
Matched conditions: REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA
Phase: NA • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo shows promise for rare blood cancer
Disease control OngoingThis early-stage study tested a combination of two drugs (pembrolizumab and pralatrexate) in 13 people with peripheral T-cell lymphoma that had returned or not responded to prior treatment. The goal was to find the safest dose and see if the combo could shrink tumors. The approac…
Matched conditions: REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Cancer-Fighting virus teams up with immunotherapy to tackle rare skin tumors
Disease control OngoingThis phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …
Matched conditions: REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Two-Drug attack on tough lymphoma shows promise in early trial
Disease control OngoingThis study tests whether combining two drugs—pembrolizumab (Keytruda), which helps the immune system fight cancer, and romidepsin (Istodax), which blocks cancer cell growth—can safely treat peripheral T-cell lymphoma that has returned or not responded to prior therapy. The trial …
Matched conditions: REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC